

CURRENT REPORT 26/2024

June 27th, 2024

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 27th, 2024

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company", "Ryvu") hereby announces that the following shareholders controlled at least 5% of the vote at the General Shareholders Meeting of the Company ("General Meeting") convened on June 27th, 2024:

1. Paweł Przewięźlikowski: 4,016,098 shares of the Company, which entitled to exercise 7,516,985 votes, which constituted respectively 29.02% of shares at the GM and 43.34% of votes at the GM and 27.66% in the total number of votes.
2. Nationale-Nederlanden Otwarty Fundusz Emerytalny: 1,511,359 shares in the Company, which entitled to exercise 1,511,359 votes, which constituted 10.92% of shares at the GM and 8.72% of votes at the GM and 5.56% of the total number of votes.
3. Towarzystwo Funduszy Inwestycyjnych Allianz Polska S.A.: 2,252,690 shares in the Company, which entitled to exercise 2,252,690 votes, representing 16.27% of shares at the GM 12.99% of votes at the GM and 8.29% of the total number of votes.
4. Allianz Polska Otwarty Fundusz Emerytalny: 2,132,000 shares of the Company, which entitled to exercise 2,132,000 votes, which constituted respectively 15.41% of shares at the GM and 12.30% of votes at the GM and 7.85% in the total number of votes.
5. Otwarty Fundusz Emerytalny PZU "Złota Jesień": 1,028,913 shares of the Company, which entitled to exercise 1,028,913 votes, which constituted respectively 7.43% of shares at the GM and 3% of votes at the GM and 3.79% in the total number of votes.
6. BioNTech SE: 1,917,437 shares of the Company, which entitled to exercise 1,917,437 votes, which constituted respectively 13.85% of shares at the GM and 11.06% of votes at the GM and 7.06% in the total number of votes.

According to the attendance list, shareholders holding 13,841,919 shares entitling them to exercise 17,341,919 votes were represented at the GM.

The total number of shares in the Company is 23,120,148, entitling to 27,170,148 votes.

Disclaimer: This English language translation has been prepared solely for the convenience of English speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 56.1.2 of the Act on Offerings

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board